Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jornay PM in Adult ADHD
NCT06577779Phase 4Recruiting
- Sponsor
- NYU Langone Health
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by NYU Langone Health. Started Jan 2025; status: recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06577779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577779.